Valeant Pharmaceuticals International (VRX) is under pressure this morning after a New York Times article entitled "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers."
Valeant Pharmaceuticals International gapped open lower this morning and has continued to decline in early trade. Shares are now down 10.17 at $172.15. The stock is trading near the middle of a 1-week range.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.